Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Resectable Pancreatic Cancer 1 Pancreatic Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Adenocarcinoma 1

Interventions

Oxaliplatin 9 Capecitabine 9 pembrolizumab 7 Paclitaxel 7 Fluorouracil 7 Leucovorin 6 Cisplatin 6 zolbetuximab 5 Gemcitabine 4 trastuzumab deruxtecan 3 enzalutamide 3 durvalumab 3 cemiplimab 3 Trastuzumab 3 Pemetrexed 3 Docetaxel 3 Carboplatin 3 130-nm albumin-bound paclitaxel 3 fludarabine 2 Taxes 2 Ramucirumab 2 Radiotherapy, Image-Guided 2 Radiosurgery 2 Nivolumab 2 Irinotecan 2 Cyclophosphamide 2 Androgen Antagonists 2 Albumin-Bound Paclitaxel 2 vistusertib 1 tucatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × paricalcitol × 90 days × Clear all

NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed

34 enrolled 11 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡